FreeTheAI

Pulse Biosciences Completes Enrollment in Pivotal Trial for nPulse Cardiac Catheter

BullishMedium impact
PLSE$53.81 7.66%

Pulse Biosciences, Inc. (PLSE) has finished patient enrollment for its pivotal trial evaluating the nPulse cardiac catheter in atrial fibrillation treatment. The clinical study, known as the NANOPULSE-AF IDE trial, reached its target with 164 evaluable patients enrolled across 15 clinical sites.

Completing trial enrollment marks a key milestone in bringing the medical device closer to commercial and regulatory evaluations. Alongside the clinical milestone, the medical technology firm also showcased preclinical progress for treating ventricular arrhythmias using two prototype endocardial catheters during a presentation in New York on October 10, 2026. Shares of the company rose 7.66% to $53.81 following the developments.

Investors and clinical researchers will watch for primary endpoint evaluations from the NANOPULSE-AF trial, which are scheduled to be assessed at 6 months and 12 months following patient ablation procedures.

Key points

  • Pulse Biosciences, Inc. completed enrollment in its NANOPULSE-AF IDE pivotal trial.
  • The study enrolled 164 evaluable patients using the nPulse cardiac catheter across 15 sites.
  • Primary study endpoints will be evaluated at 6 and 12 months following patient ablation.
  • The company showcased preclinical advances for two prototype endocardial catheters in New York.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

How many patients were enrolled in the Pulse Biosciences trial?

The NANOPULSE-AF IDE trial completed enrollment with 164 evaluable patients across 15 sites.

When will results from the NANOPULSE-AF study be evaluated?

Primary endpoints for the trial will be assessed at 6 months and 12 months post-ablation.

What other updates did Pulse Biosciences report?

The company presented preclinical advances for ventricular arrhythmia ablation from two prototype endocardial catheters on October 10, 2026.